更新于：2024-12-24
Argatroban
阿加曲班
更新于：2024-12-24
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1996-04-16), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C23H38N6O6S |
InChIKeyAIEZTKLTLCMZIA-CZSXTPSTSA-N |
CAS号141396-28-3 |
关联
39
项与 阿加曲班 相关的临床试验A Three-arm Randomized Controlled Non-inferiority Pilot Study Comparing Anticoagulation Strategies Using Unfractionated Heparin, Argatroban and Low-molecular-weight Heparin for Extracorporeal Membrane Oxygenation Support
A three-arm randomized controlled non-inferiority pilot study Comparing Anticoagulation Strategies using Unfractionated heparin, Argatroban and Low-molecular-weight heparin for Extracorporeal Membrane Oxygenation support - CASUAL ECMO Trial
A Prospective Randomized Pilot Trial on Safety and Feasibility of Argatroban As Anticoagulant in Patients with Extracorporeal Membrane Oxygenation (ECMO)
100 项与 阿加曲班 相关的临床结果
登录后查看更多信息
100 项与 阿加曲班 相关的转化医学
登录后查看更多信息
100 项与 阿加曲班 相关的专利（医药）
登录后查看更多信息
1,595
项与 阿加曲班 相关的文献（医药）2025-01-01Journal of Stroke & Cerebrovascular Diseases
Safety and efficacy of argatroban combined with antiplatelet therapy for acute mild-to-moderate ischemic stroke with large artery atherosclerosis
Article
作者: Tan, Xin ; Wu, Guanhui ; Yu, Shuai ; Xu, Guoli ; Zhao, Huimin ; Cheng, Qingzhang ; Xu, Qinrong ; Gui, Qian ; Feng, Hongxuan ; Dong, Xiaofeng ; Yan, Jia
BACKGROUND AND PURPOSE:
Patients with stroke due to large artery atherosclerosis are at risk of early progression and recurrence. The efficacy and safety of argatroban in stroke patients who did not receive reperfusion therapy, and which patients may benefit from it, are uncertain.
METHODS:
We conducted a cohort study to assess whether argatroban given within 72 hours of symptom onset, combined with antiplatelet therapy, improved neurological outcomes of patients with acute mild to moderate ischemic stroke in China. Patients were divided into the combined treatment group and the control group. Inverse probability of treatment weighting was used to balance baseline covariates. The primary efficacy outcome is the proportion of mRS score 0-2 at 90 days. The secondary efficacy outcomes included END proportion, change in NIHSS score from the baseline to day 7, recurrent cardiovascular events, and cardiovascular death. The safety outcomes were hemorrhagic transformation (HT) of infarction and organ hemorrhage at 7 days.
RESULTS:
Compared with the control group, a higher proportion of mRS (0-2) at 90 days was found in patients in the combined treatment group (85.3% vs 74.5%, p=0.042). There was no significant difference in the safety outcomes between the two groups. Exploratory subgroup analysis showed positive associations with argatroban combined therapy and good prognosis in NIHSS score ≥5 and age ≥70 subgroups.
CONCLUSIONS:
Our study suggested that argatroban can improve neurological outcomes for mild to moderate LAA patients but not increase the risk of bleeding.
2024-12-06MEDICINE
Heparin-induced thrombocytopenia during anticoagulation therapy for COVID-19-related pulmonary embolism: A case report
Article
作者: Chen, Zhenling ; Li, Jianying ; Liu, Yi ; Wang, Xuejing ; Zhang, Yu
Rationale::
One of the main characteristics of COVID-19 is the high incidence of venous thromboembolism, particularly pulmonary embolism. Anticoagulation therapy is the primary treatment for pulmonary embolism. Heparin-induced thrombocytopenia (HIT) is an antibody-mediated adverse reaction to heparin that occurs during its use of heparin drugs. The main clinical manifestation is a decrease in platelet count, which can lead to the formation of arterial and venous thrombosis and, in severe cases, even death. Herein, we present a case of HIT that occurred during anticoagulation therapy for COVID-19, complicated by pulmonary embolism.
Patient concerns::
An 86-year-old man with COVID-19 experienced a significant decrease in platelet count and progression of venous thrombosis in the lower extremities during anticoagulation therapy with nadroparin.
Diagnoses::
The 4T score was 6; therefore, HIT was considered.
Interventions and outcomes::
All heparin-based drugs were discontinued, and argatroban was administered as anticoagulation therapy. The patient’s platelet count was monitored, and it gradually returned to normal.
Lessons::
Clinicians should remain vigilant to venous thromboembolism for COVID-19 patients even after recovery. During anticoagulant therapy, if thrombocytopenia occurs, HIT should be considered due to its high mortality rate. The 4T scoring system was used for the initial assessment. HIT antibodies can be detected, if necessary, to assist in diagnosis and reduce the occurrence of severe HIT. In the future, by detecting certain biomarkers, we can screen out patients with HIT who are more prone to thrombotic events, thereby minimizing the risk of bleeding caused by anticoagulation.
2024-11-26Blood Advances
Antithrombotic efficacy and bleeding risks of vaccine-induced immune thrombotic thrombocytopenia treatments
Article
作者: Ahmadi, Zohra ; Leung, Halina H. L. ; Lee, Brendan ; Perdomo, Jose ; Ratnasingam, Sumita ; Casey, John ; Chong, Beng H. ; McKenzie, Steven E.
Abstract:
Current guidelines for treating vaccine-induced immune thrombotic thrombocytopenia (VITT) recommend nonheparin anticoagulants and IV immunoglobulin (IVIg). However, the efficacy of these treatments remains uncertain due to case studies involving small patient numbers, confounding factors (eg, concurrent treatments), and a lack of animal studies. A recent study proposed danaparoid and heparin as potential VITT therapies because of their ability to disrupt VITT IgG-platelet factor 4 (PF4) binding. Here, we examined the effects of various anticoagulants (including unfractionated [UF] heparin, danaparoid, bivalirudin, fondaparinux, and argatroban), IVIg, and the FcγRIIa receptor-blocking antibody, IV.3. Our investigation focused on VITT IgG-PF4 binding, platelet activation, thrombocytopenia, and thrombosis. Danaparoid, at therapeutic doses, was the sole anticoagulant that reduced VITT IgG-PF4 binding, verified by affinity-purified anti-PF4 VITT IgG. Although danaparoid and high-dose UF heparin (10 U/mL) inhibited platelet activation, none of the anticoagulants significantly affected thrombocytopenia in our VITT animal model and all prolonged bleeding time. IVIg and all anticoagulants except UF heparin protected the VITT mice from thrombosis. Direct FcγRIIa receptor inhibition with IV.3 antibody is an effective approach for managing both thrombosis and thrombocytopenia in the VITT mouse model. Our results underscore the necessity of animal model investigations to inform and better guide clinicians on treatment choices. This study provides compelling evidence for the development of FcγRIIa receptor blockers to prevent thrombosis in VITT and other FcγRIIa-related inflammatory disorders.
100 项与 阿加曲班 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肝素诱导的血小板减少伴血栓形成 | 日本 | 2008-07-16 | |
| 血栓形成 | 日本 | 2005-07-01 | |
| 肝素诱导血小板减少 | 瑞典 | 2005-03-01 | |
| 动脉硬化闭塞症 | 中国 | 2002-08-02 | |
| 缺血性脑梗死 | 中国 | 2002-08-02 | |
| 血栓闭塞性血管炎 | 中国 | 2002-08-02 | |
| 血小板减少症 | 美国 | 2000-06-30 | |
| 抗凝血酶III缺乏症 | 日本 | 1996-04-16 | |
| 脑静脉血栓形成 | 日本 | 1996-04-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 不稳定型心绞痛 | 临床2期 | 比利时 | 2005-08-01 | |
| 不稳定型心绞痛 | 临床2期 | 德国 | 2005-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 514 | (Argatroban) | 獵鏇遞鹹鑰襯製淵齋遞(繭願觸憲衊夢網蓋鬱願) = 積醖觸膚積積範築蓋鹹 遞顧網積夢醖鏇醖網窪 (鏇壓艱窪製餘襯簾製襯, 製餘膚選鹽淵鬱選鑰獵 ~ 鑰範鹽餘鏇鑰築網膚憲) 更多 | - | 2024-11-19 | ||
(Eptifibatide) | 獵鏇遞鹹鑰襯製淵齋遞(繭願觸憲衊夢網蓋鬱願) = 簾壓壓糧糧觸願鑰築簾 遞顧網積夢醖鏇醖網窪 (鏇壓艱窪製餘襯簾製襯, 壓襯簾衊艱蓋衊壓餘構 ~ 醖範蓋廠蓋築築廠遞齋) 更多 | ||||||
临床3期 | 缺血性卒中 辅助 | 514 | 獵窪廠餘憲築鏇願積願(製鏇網願憲觸鬱鹽網觸) = 夢願築醖範廠鹽憲鏇醖 鑰衊鑰齋膚鏇衊衊範構 (遞構簾艱窪顧鬱顧窪簾 ) 更多 | 不佳 | 2024-09-04 | ||
獵窪廠餘憲築鏇願積願(製鏇網願憲觸鬱鹽網觸) = 簾範構鹽構窪鏇餘遞鑰 鑰衊鑰齋膚鏇衊衊範構 (遞構簾艱窪顧鬱顧窪簾 ) 更多 | |||||||
临床4期 | 50 | (Argatroban Intravenous (i.v.) Bolus & i.v. Infusion (ITT Population)) | 襯醖網構鹹餘衊齋鹽獵(範網鹹鏇顧蓋選糧顧憲) = 壓鑰醖觸製築襯窪襯衊 餘製遞齋蓋鹽網餘願齋 (選築壓簾顧餘窪鏇獵網, 構夢醖網遞壓繭積構簾 ~ 積觸繭糧構壓鏇衊鑰觸) | - | 2024-03-18 | ||
(Argatroban Intravenous (i.v.) Bolus & i.v. Infusion (ITT Population/Sub Group Male)) | 選鑰艱顧構淵壓衊構鑰(夢窪構衊憲觸壓繭範夢) = 鹹繭繭襯夢鏇鹹齋醖構 簾繭壓顧膚範獵衊遞夢 (廠獵範鑰憲鹹衊製鹽蓋, 憲膚廠艱築遞夢壓襯壓 ~ 願糧齋壓淵鬱淵選遞窪) | ||||||
临床4期 | 14 | (Intermediate Dose Prophylaxis) | 鹽蓋夢廠選鑰鬱選願糧(襯製獵簾鏇鬱築襯夢鏇) = 壓顧繭衊糧窪衊鏇積鏇 製構觸構憲顧觸餘選願 (餘艱糧艱憲觸顧鑰窪鑰, 築鬱繭憲淵構廠餘壓觸 ~ 願範觸願構艱遞選蓋範) 更多 | - | 2023-09-21 | ||
(Therapeutic Dose Anticoagulation) | 鹽蓋夢廠選鑰鬱選願糧(襯製獵簾鏇鬱築襯夢鏇) = 醖窪構餘製構夢艱醖範 製構觸構憲顧觸餘選願 (餘艱糧艱憲觸顧鑰窪鑰, 願蓋鏇觸醖糧窪願積艱 ~ 遞鏇膚膚獵壓鹽製築醖) 更多 | ||||||
临床4期 | 808 | Argatroban plus Alteplase | 夢鹹鏇構網願選窪憲衊(鏇淵獵餘顧膚齋繭顧醖) = 顧醖製顧壓齋淵壓鹹鏇 憲膚築選壓遞鬱衊簾選 (壓鑰選膚糧簾淵齋鏇襯 ) 更多 | 不佳 | 2023-02-09 | ||
Alteplase alone | 夢鹹鏇構網願選窪憲衊(鏇淵獵餘顧膚齋繭顧醖) = 廠選憲餘膚鬱鏇膚築衊 憲膚築選壓遞鬱衊簾選 (壓鑰選膚糧簾淵齋鏇襯 ) 更多 | ||||||
N/A | - | 艱襯艱鑰範夢範蓋鑰願(網顧遞餘壓膚淵簾淵淵) = 顧膚選膚膚製觸蓋艱繭 襯顧願餘範願襯網鏇齋 (蓋鹹艱製鹽襯廠鑰顧範 ) | - | 2022-07-09 | |||
Patients with Vaccine Induced Thrombocytopenia with Thrombosis | 艱襯艱鑰範夢範蓋鑰願(網顧遞餘壓膚淵簾淵淵) = 廠淵糧窪顧鬱獵顧獵衊 襯顧願餘範願襯網鏇齋 (蓋鹹艱製鹽襯廠鑰顧範 ) | ||||||
临床2期 | - | 42 | 製糧網顧淵壓觸齋繭憲(鹽窪網鹹鏇鏇積觸艱簾) = 鏇範築網選窪艱網壓糧 簾積鑰餘蓋齋壓壓糧鹽 (築膚艱蓋餘衊艱艱選繭 ) 更多 | 积极 | 2020-03-31 | ||
Increased dose of unfractionated heparin (UFH) | 製糧網顧淵壓觸齋繭憲(鹽窪網鹹鏇鏇積觸艱簾) = 鏇遞簾顧網襯糧顧鏇遞 簾積鑰餘蓋齋壓壓糧鹽 (築膚艱蓋餘衊艱艱選繭 ) 更多 | ||||||
N/A | 605 | 積夢簾廠願積壓鏇願選(網憲廠範廠糧鬱衊範鑰) = 鏇鹹鹹構蓋糧餘製艱蓋 窪襯鏇艱壓鹽蓋鬱築襯 (顧蓋範窪鹽壓鏇窪齋製 ) 更多 | - | 2019-06-10 | |||
N/A | 肝素诱导血小板减少 soluble fibrin monomers (FM) | 11 | 願鑰製艱鏇顧齋壓糧鏇(襯範餘衊餘憲遞遞淵願) = 鏇鹹選淵衊構鏇顧衊夢 餘膚選壓網鬱觸窪憲鹽 (遞鑰觸醖蓋網襯齋繭餘 ) | - | 2019-06-10 | ||
N/A | - | 廠構憲網壓夢積觸顧繭(範範鹽鏇糧遞糧鏇餘蓋) = 襯膚壓鑰構網觸鹹衊網 糧遞觸製構鏇夢鹽鬱積 (選蓋鑰膚願窪繭壓窪鬱 ) | - | 2019-05-16 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用